Efficacy of Favipiravir Against Ebola (JIKI)

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2015

Conditions
Ebola Virus Disease
Interventions
DRUG

Favipiravir

"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."

Trial Locations (4)

Unknown

The caregivers treatment center, Conakry

MSF Ebola treatment centre, Gueckedou

French Red Cross Ebola care center, Macenta

ALIMA Ebola care center, Nzérékoré

All Listed Sponsors
lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT02329054 - Efficacy of Favipiravir Against Ebola (JIKI) | Biotech Hunter | Biotech Hunter